Ignite Creation Date:
2024-05-06 @ 5:50 PM
Last Modification Date:
2024-10-26 @ 2:37 PM
Study NCT ID:
NCT05455619
Status:
RECRUITING
Last Update Posted:
2024-05-22
First Post:
2022-06-22
Brief Title:
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Women With a PI3K Alteration and HRHer2- Breast Cancer
Sponsor:
Organization:
SynDevRx Inc